Ceftaroline Fosamil in Subjects With Staphylococcus aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
-
Investigator: Henry Chambers, MD
Sponsor: Cerexa, Inc
Location(s): United States
Description
This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.